Small Molecule Inhibitors for Hepatocellular Carcinoma: Advances and Challenges

HIGHLIGHTS: Multi tyrosine kinase inhibitors licensed for HCC treatment. Multi kinase inhibitors not licensed for HCC treatment. Inhibitors of Growth Factor Receptors. Small molecules acting as immunomodulators. Small molecules inhibiting crucial HCC pathways. Small molecules targeting various molec...

Descripción completa

Detalles Bibliográficos
Autores principales: Kamal, Monica A., Mandour, Yasmine M., Abd El-Aziz, Mostafa K., Stein, Ulrike, El Tayebi, Hend M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9457820/
https://www.ncbi.nlm.nih.gov/pubmed/36080304
http://dx.doi.org/10.3390/molecules27175537

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9457820/
https://www.ncbi.nlm.nih.gov/pubmed/36080304
http://dx.doi.org/10.3390/molecules27175537

Ejemplares similares